- Home
- GHRS vs DIAX Comparison
GHRS vs DIAX Comparison
Compare GHRS & DIAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- DIAX
- Stock Information
- Founded
- GHRS 2018
- DIAX 2005
- Country
- GHRS Ireland
- DIAX United States
- Employees
- GHRS N/A
- DIAX N/A
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- DIAX Finance Companies
- Sector
- GHRS Health Care
- DIAX Finance
- Exchange
- GHRS Nasdaq
- DIAX Nasdaq
- Market Cap
- GHRS 462.0M
- DIAX 552.4M
- IPO Year
- GHRS 2021
- DIAX N/A
- Fundamental
- Price
- GHRS $8.99
- DIAX $15.52
- Analyst Decision
- GHRS Strong Buy
- DIAX
- Analyst Count
- GHRS 3
- DIAX 0
- Target Price
- GHRS $35.67
- DIAX N/A
- AVG Volume (30 Days)
- GHRS 89.4K
- DIAX 96.6K
- Earning Date
- GHRS 02-27-2025
- DIAX 01-01-0001
- Dividend Yield
- GHRS N/A
- DIAX 7.93%
- EPS Growth
- GHRS N/A
- DIAX N/A
- EPS
- GHRS N/A
- DIAX N/A
- Revenue
- GHRS N/A
- DIAX N/A
- Revenue This Year
- GHRS N/A
- DIAX N/A
- Revenue Next Year
- GHRS N/A
- DIAX N/A
- P/E Ratio
- GHRS N/A
- DIAX N/A
- Revenue Growth
- GHRS N/A
- DIAX N/A
- 52 Week Low
- GHRS $5.92
- DIAX $12.80
- 52 Week High
- GHRS $14.99
- DIAX $15.12
- Technical
- Relative Strength Index (RSI)
- GHRS 58.18
- DIAX 63.15
- Support Level
- GHRS $8.02
- DIAX $14.66
- Resistance Level
- GHRS $10.23
- DIAX $15.17
- Average True Range (ATR)
- GHRS 0.90
- DIAX 0.19
- MACD
- GHRS 0.11
- DIAX 0.06
- Stochastic Oscillator
- GHRS 62.20
- DIAX 100.00
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.